Transaction #14848 · Form 4 · 0001894425-25-000010
NEUROCRINE BIOSCIENCES INC · Exercise / conversion · Common Stock
NEUROCRINE BIOSCIENCES INC · Transacted November 29, 2025 · Filed December 2, 2025
What does this filing report?
An SEC Form 4 filing for NEUROCRINE BIOSCIENCES INC records an exercise / conversion involving Common Stock on November 29, 2025. The reported quantity was 4,426. The filing date is December 2, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- NEUROCRINE BIOSCIENCES INC
- Company CIK
- 0000914475
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 4,426
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 18,129
- Ownership description
- Not reported
- SEC acceptance time
- Dec 2, 2025, 5:14 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Onyia Jude ↗
Chief Scientific Officer
CIK 0001894425
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Shares withheld by Neurocrine Biosciences, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
- F2
- Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock.
- F3
- This RSU was granted to the Reporting Person on November 29, 2021. In accordance with the terms of the RSU, the award vested as to 4,425 shares on November 29, 2022, vested as to 4,425 shares on November 29, 2023, vested as to 4,426 shares on November 29, 2024, and vested as to 4,426 shares on November 29, 2025, subject to the terms and conditions of the award.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.